carmustine and Disease Exacerbation studies

Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.

Research Excerpts

Excerpt	Relevance	Reference
"To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma."	9.20	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015)
"We have undertaken a retrospective sequential-cohort analysis of 131 lymphoma patients treated with the BEAM regimen and autologous stem cell transplantation, to compare BEAM at standard doses (sBEAM; n = 67 from May 1990 to April 1995) and BEAM with escalated etoposide dose from 800 to 1600 mg/m(2) (eBEAM; n = 64 from May 1995 to June 1999)."	9.11	Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. ( Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA, 2004)
"1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) induces DNA damage via a chloroethyl adduct at the O(6) position of guanine, which can be repaired by O(6)-alkylguanine DNA alkyltransferase (AGT) expressed in melanoma."	9.11	Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. ( Dolan, E; Gajewski, TF; Gerson, SL; Lin, S; Liu, L; Sosman, J; Vokes, EE, 2005)
"Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)."	9.11	Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004)
"This phase III Eastern Cooperative Oncology Group-Southwest Oncology Group intergroup study was conducted to determine whether three 72-hour infusions of carmustine (BiCNU) and cisplatin administered monthly before external-beam radiotherapy would improve the survival of patients with newly diagnosed glioblastoma multiforme."	9.10	Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol ( Gilbert, M; Grossman, SA; Grunnet, M; Hellman, R; Mehta, M; Newton, HB; O'Neill, A; Pearlman, JL; Wagner, H, 2003)
"The use of thalidomide as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas."	9.10	Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003)
"The current study was conducted to determine whether the addition of interferon-alpha (IFN-alpha) to treatment with radiation therapy and carmustine (BCNU) improves time to disease progression or overall survival in patients with high-grade glioma."	9.09	A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. ( Bernath, AM; Buckner, JC; Cascino, TL; Cole, JT; Hatfield, AK; Kuross, SA; Mailliard, JA; McGinnis, WL; Morton, RF; O'Fallon, JR; Scheithauer, BW; Schomberg, PJ; Steen, PD, 2001)
"The purpose of this study was to compare the response rate, overall and 1-year survival in patients with advanced melanoma treated with a standard therapy, dacarbazine and interferon-alpha (DTIC/IFN), or combination chemotherapy, consisting of dacarbazine, BCNU, cisplatin and tamoxifen (DBCT)."	9.09	A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. ( Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N, 2000)
"The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)."	7.73	Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005)
" Three patients were treated at each dosing level (AUC=2-6), and 4 patients were treated at an AUC=5."	6.71	A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. ( Asher, A; Fraser, R; Heafner, M; Kim, JW; Limentani, SA, 2005)
"The outcome after treatment for glioblastoma remains poor."	6.69	Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998)
" We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT."	5.42	High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. ( Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A, 2015)
"During follow-up, local disease progression was observed in 27 patients, and 23 of them died."	5.35	Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. ( Albright, RE; Breneman, JC; Darakchiev, BJ; Warnick, RE, 2008)
"To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma."	5.20	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015)
"1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) induces DNA damage via a chloroethyl adduct at the O(6) position of guanine, which can be repaired by O(6)-alkylguanine DNA alkyltransferase (AGT) expressed in melanoma."	5.11	Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. ( Dolan, E; Gajewski, TF; Gerson, SL; Lin, S; Liu, L; Sosman, J; Vokes, EE, 2005)
"Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)."	5.11	Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004)
"We have undertaken a retrospective sequential-cohort analysis of 131 lymphoma patients treated with the BEAM regimen and autologous stem cell transplantation, to compare BEAM at standard doses (sBEAM; n = 67 from May 1990 to April 1995) and BEAM with escalated etoposide dose from 800 to 1600 mg/m(2) (eBEAM; n = 64 from May 1995 to June 1999)."	5.11	Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. ( Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA, 2004)
"The use of thalidomide as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas."	5.10	Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003)
"This phase III Eastern Cooperative Oncology Group-Southwest Oncology Group intergroup study was conducted to determine whether three 72-hour infusions of carmustine (BiCNU) and cisplatin administered monthly before external-beam radiotherapy would improve the survival of patients with newly diagnosed glioblastoma multiforme."	5.10	Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol ( Gilbert, M; Grossman, SA; Grunnet, M; Hellman, R; Mehta, M; Newton, HB; O'Neill, A; Pearlman, JL; Wagner, H, 2003)
"The purpose of this study was to compare the response rate, overall and 1-year survival in patients with advanced melanoma treated with a standard therapy, dacarbazine and interferon-alpha (DTIC/IFN), or combination chemotherapy, consisting of dacarbazine, BCNU, cisplatin and tamoxifen (DBCT)."	5.09	A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. ( Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N, 2000)
"The current study was conducted to determine whether the addition of interferon-alpha (IFN-alpha) to treatment with radiation therapy and carmustine (BCNU) improves time to disease progression or overall survival in patients with high-grade glioma."	5.09	A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. ( Bernath, AM; Buckner, JC; Cascino, TL; Cole, JT; Hatfield, AK; Kuross, SA; Mailliard, JA; McGinnis, WL; Morton, RF; O'Fallon, JR; Scheithauer, BW; Schomberg, PJ; Steen, PD, 2001)
"Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy."	4.90	The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. ( Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY, 2014)
"In situ carmustine wafers containing 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) are commonly used for the treatment of recurrent glioblastoma to overcome the brain-blood barrier."	3.88	Incomplete copolymer degradation of in situ chemotherapy. ( Apra, C; Boissenot, T; Bourdillon, P; Carpentier, A; Goldwirt, L; Nicolas, J, 2018)
" The purpose of this study was to investigate the efficacy of concurrent therapy with 1,3 bis[2-chloroethyl]-1-nitrosourea (BCNU; carmustine) and Gamma Knife radiosurgery (GKRS; Gamma Knife® Model C, Elekta AB, Stockholm, Sweden) in the C6 rat glioma model."	3.78	Concurrent treatment with BCNU and Gamma Knife radiosurgery in the rat malignant glioma model. ( Cho, KT; Chung, HT; Jung, HW; Kim, DG; Paek, SH; Park, HW, 2012)
"Twenty-seven children and adolescents with malignant astrocytomas [17 glioblastoma multiforme and 10 anaplastic astrocytoma (AA)] following initial tumor progression, received myeloablative chemotherapy followed by autologous marrow rescue with one of three thiotepa and etoposide-based chemotherapy regimens, administered alone (n = 11) or combined with carmustine (n = 5) or carboplatin (n = 11)."	3.74	Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. ( Boyett, JM; Dhall, G; Dunkel, IJ; Finlay, JL; Gardner, SL; Goldman, S; Packer, RJ; Pollack, IF; Rosenblum, MK; Stanley, P; Wallace, D; Yates, AJ; Zimmerman, RA, 2008)
"The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)."	3.73	Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005)
"A retrospective study of 30 cases of Hodgkin disease in patients who underwent high-dose carmustine, etoposide, and cyclophosphamide chemotherapy with PBSC support was performed."	3.70	Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin disease. ( Bogart, JA; Chung, CT; Ryu, S; Ungureanu, C; Zamkoff, KW, 2000)
"We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery."	3.70	Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999)
" Three patients were treated at each dosing level (AUC=2-6), and 4 patients were treated at an AUC=5."	2.71	A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. ( Asher, A; Fraser, R; Heafner, M; Kim, JW; Limentani, SA, 2005)
" The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days."	2.70	Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. ( Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001)
"The outcome after treatment for glioblastoma remains poor."	2.69	Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998)
"In all cases, the ras mutation of the disease progression sample was identical to that found at diagnosis."	2.68	Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. ( Billadeau, D; Greipp, P; Kay, NE; Kyle, RA; Leong, T; Liu, P; Oken, MM; Quam, L; Van Ness, B, 1996)
" We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT."	1.42	High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. ( Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A, 2015)
" Their AEs were examined clinically and radiologically and evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) grading."	1.42	[Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas]. ( Asaoka, K; Endo, S; Houkin, K; Ishi, Y; Kamoshima, Y; Kobayashi, H; Motegi, H; Terasaka, S; Yamaguchi, S; Yoshida, M, 2015)
"Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity."	1.35	High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. ( Caballero, D; Canals, C; Finke, J; Goldstone, A; Hunter, A; Kienast, J; Kobbe, G; Kolb, HJ; Kyriakou, C; Metzner, B; Oberg, G; Reimer, P; Schmitz, N; Sureda, A; Theorin, N, 2008)
"During follow-up, local disease progression was observed in 27 patients, and 23 of them died."	1.35	Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. ( Albright, RE; Breneman, JC; Darakchiev, BJ; Warnick, RE, 2008)
"Histology included anaplastic astrocytoma (60) (AA), and glioblastoma multiforme (312) (GBM)."	1.34	Imaging response in malignant glioma, RTOG 90-06. ( Berkey, B; Curran, WJ; Fishbach, J; Jones, CU; Lustig, RA; Movsas, B; Scarantino, C; Seiferheld, W; Simpson, JR; Yung, AW, 2007)
"Patients who had disease bulk at recurrence that measured > 5 cm received involved-field radiation post-ASCT."	1.33	Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation ( Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R, 2006)
"The median time to disease progression and median survival were 1."	1.31	Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. ( Blume, KG; Chao, NJ; Feiner, RH; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Wong, RM, 2000)
"The probability of disease progression at 1 year for patients with chemoresistant and chemosensitive disease were 75% and 25%, respectively (P =."	1.31	Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. ( Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G, 2002)
"Despite the fact that follicular lymphomas are both chemo- and radiosensitive, the disease is generally non-curable."	1.31	Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. ( Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H, 2000)
"Bone resorption was assessed by urinary free pyridinoline (fPyr) and deoxypyridinoline (fDPyr), expressed as a ratio of the urinary creatinine concentration."	1.31	Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. ( Clark, RE; Durham, BH; Flory, AJ; Fraser, WD; Ion, EM; Woodcock, BE, 2000)
" HDT appeared to be somewhat more toxic in the elderly patients: a higher peak CRP value (P = 0."	1.31	Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. ( Jantunen, E; Mahlamäki, E; Nousiainen, T, 2000)
"One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved."	1.30	Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. ( Chen, MG; Gastineau, DA; Gertz, MA; Greipp, PR; Inwards, DJ; Kyle, RA; Lacy, MQ; Litzow, MR; Lust, JA; Pineda, AA; Tefferi, A; Witzig, TE, 1999)

Research

Studies (65)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Maximum Tolerated Dose (MTD) of Ipilimumab

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	12 (18.46)	18.2507
2000's	38 (58.46)	29.6817
2010's	15 (23.08)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Bourdillon, P	1
Boissenot, T	1
Goldwirt, L	1
Nicolas, J	1
Apra, C	1
Carpentier, A	1
Ng, ZY	1
Bishton, M	1
Ritchie, D	1
Campbell, R	1
Gilbertson, M	1
Hill, K	1
Ratnasingam, S	1
Schwarer, A	1
Manos, K	1
Shorten, S	1
Ng, M	1
Nelson, N	1
Xin, L	1
De Mel Widanalage, S	1
Sunny, T	1
Purtill, D	1
Poon, M	1
Johnston, A	1
Cochrane, T	1
Lee, HP	1
Hapgood, G	1
Tam, C	1
Opat, S	1
Hawkes, E	1
Seymour, J	1
Cheah, CY	1
Sobol, U	1
Rodriguez, T	1
Smith, S	1
Go, A	1
Vimr, R	1
Parthasarathy, M	1
Guo, R	1
Stiff, P	1
Pytlík, R	1
Belada, D	1
Kubáčková, K	1
Vášová, I	1
Kozák, T	1
Pirnos, J	1
Bolomská, I	1
Matuška, M	1
Přibylová, J	1
Campr, V	1
Burešová, L	1
Sýkorová, A	1
Berková, A	1
Klener, P	1
Trněný, M	1
Olson, JJ	1
Nayak, L	1
Ormond, DR	1
Wen, PY	2
Kalkanis, SN	1
Martin, N	1
Borchiellini, D	1
Coso, D	1
Gastaud, L	1
Boscagli, A	1
Saudes, L	1
Re, D	1
Gutnecht, J	1
Garnier, G	1
Petit, E	1
Barriere, J	1
Naman, H	1
Rossignol, B	1
Thyss, A	1
Peyrade, F	1
de Quintana-Sancho, A	1
Acebo-Mariñas, E	1
Gardeazabal-García, J	1
Aperribay-Esparza, A	1
Yoshida, M	1
Yamaguchi, S	1
Ishi, Y	1
Endo, S	1
Motegi, H	1
Kobayashi, H	1
Asaoka, K	1
Kamoshima, Y	1
Terasaka, S	1
Houkin, K	1
Yamano, S	1
Gi, M	1
Tago, Y	1
Doi, K	1
Okada, S	1
Hirayama, Y	1
Tachibana, H	1
Ishii, N	1
Fujioka, M	1
Tatsumi, K	1
Wanibuchi, H	1
Stupp, R	1
Taillibert, S	1
Kanner, AA	1
Kesari, S	1
Steinberg, DM	1
Toms, SA	1
Taylor, LP	1
Lieberman, F	1
Silvani, A	3
Fink, KL	2
Barnett, GH	1
Zhu, JJ	1
Henson, JW	1
Engelhard, HH	1
Chen, TC	1
Tran, DD	1
Sroubek, J	1
Tran, ND	1
Hottinger, AF	1
Landolfi, J	1
Desai, R	1
Caroli, M	1
Kew, Y	1
Honnorat, J	1
Idbaih, A	1
Kirson, ED	1
Weinberg, U	1
Palti, Y	1
Hegi, ME	1
Ram, Z	1
Mathios, D	1
Kim, JE	1
Mangraviti, A	1
Phallen, J	1
Park, CK	1
Jackson, CM	1
Garzon-Muvdi, T	1
Kim, E	1
Theodros, D	1
Polanczyk, M	1
Martin, AM	1
Suk, I	1
Ye, X	1
Tyler, B	1
Bettegowda, C	1
Brem, H	1
Pardoll, DM	1
Lim, M	1
Monfared, P	1
Winkeler, A	1
Klein, M	1
Li, H	1
Klose, A	1
Hoesel, M	1
Waerzeggers, Y	1
Korsching, S	1
Jacobs, AH	1
Finlay, JL	1
Dhall, G	1
Boyett, JM	1
Dunkel, IJ	1
Gardner, SL	1
Goldman, S	1
Yates, AJ	1
Rosenblum, MK	1
Stanley, P	1
Zimmerman, RA	1
Wallace, D	1
Pollack, IF	1
Packer, RJ	1
Corn, BW	1
Wang, M	1
Fox, S	1
Michalski, J	1
Purdy, J	1
Simpson, J	1
Kresl, J	1
Curran, WJ	2
Diaz, A	1
Mehta, M	3
Movsas, B	2
Liu, HL	1
Hua, MY	1
Chen, PY	1
Chu, PC	1
Pan, CH	1
Yang, HW	1
Huang, CY	1
Wang, JJ	1
Yen, TC	1
Wei, KC	1
Laack, NN	1
O'Neill, BP	1
Ballman, KV	1
O'Fallon, JR	3
Carrero, XW	1
Kurtin, PJ	1
Scheithauer, BW	2
Brown, PD	1
Habermann, TM	1
Colgan, JP	1
Gilbert, MR	1
Hawkins, RB	1
Morton, RF	2
Windschitl, HE	1
Fitch, TR	1
Pajon, ER	1
Cho, KT	1
Kim, DG	1
Paek, SH	1
Chung, HT	1
Jung, HW	1
Park, HW	1
Huang, HC	1
Cheng, AL	2
Lin, CW	1
Kuo, SH	1
Lush, RJ	1
Haynes, AP	1
Byrne, J	1
Cull, GM	1
Carter, GI	1
Pagliuca, A	1
Parker, JE	1
Mufti, G	1
Mahendra, P	1
Craddock, CF	1
Lui Yin, JA	1
Garg, M	1
Prentice, HG	1
Potter, MN	1
Russell, NH	1
Robinson, SP	1
Goldstone, AH	1
Mackinnon, S	1
Carella, A	1
Russell, N	1
de Elvira, CR	1
Taghipour, G	1
Schmitz, N	2
Balaña, C	1
Ramirez, JL	1
Taron, M	1
Roussos, Y	1
Ariza, A	1
Ballester, R	1
Sarries, C	1
Mendez, P	1
Sanchez, JJ	1
Rosell, R	1
Grossman, SA	1
O'Neill, A	1
Grunnet, M	1
Pearlman, JL	1
Wagner, H	1
Gilbert, M	1
Newton, HB	1
Hellman, R	1
Fine, HA	1
Maher, EA	1
Viscosi, E	1
Batchelor, T	1
Lakhani, N	1
Figg, WD	1
Purow, BW	1
Borkowf, CB	1
Rojas-Marcos, I	1
Calvet, D	1
Janoray, P	1
Delattre, JY	1
Chang, SM	2
Prados, MD	2
Yung, WK	1
Fine, H	1
Junck, L	1
Greenberg, H	1
Robins, HI	1
Jaeckle, KA	1
Kuhn, J	1
Hess, K	1
Schold, C	1
Rosenthal, MA	1
Ashley, DL	1
Cher, L	1
Martín, A	1
Caballero, MD	1
Pérez-Simón, JA	1
López-Holgado, N	1
Mateos, MV	1
Cañizo, MC	1
Miguel, JF	1
Lohani, S	1
O'Driscoll, BR	1
Woodcock, AA	1
Barrié, M	1
Couprie, C	1
Dufour, H	1
Figarella-Branger, D	1
Muracciole, X	1
Hoang-Xuan, K	1
Braguer, D	1
Martin, PM	1
Peragut, JC	1
Grisoli, F	1
Chinot, O	1
Limentani, SA	1
Asher, A	1
Heafner, M	1
Kim, JW	1
Fraser, R	1
Bobola, MS	1
Finn, LS	1
Ellenbogen, RG	1
Geyer, JR	1
Berger, MS	1
Braga, JM	1
Meade, EH	1
Gross, ME	1
Silber, JR	1
Gajewski, TF	1
Sosman, J	1
Gerson, SL	1
Liu, L	1
Dolan, E	1
Lin, S	1
Vokes, EE	1
Kuruvilla, J	1
Nagy, T	1
Pintilie, M	1
Tsang, R	1
Keating, A	1
Crump, M	1
Lustig, RA	1
Seiferheld, W	1
Berkey, B	1
Yung, AW	1
Scarantino, C	1
Jones, CU	1
Simpson, JR	1
Fishbach, J	1
Williams, KM	1
Higman, MA	1
Chen, AR	1
Schwartz, CL	1
Wharam, M	1
Colombani, P	1
Arceci, RJ	1
Kyriakou, C	1
Canals, C	1
Goldstone, A	1
Caballero, D	1
Metzner, B	1
Kobbe, G	1
Kolb, HJ	1
Kienast, J	1
Reimer, P	1
Finke, J	1
Oberg, G	1
Hunter, A	1
Theorin, N	1
Sureda, A	1
Darakchiev, BJ	1
Albright, RE	1
Breneman, JC	1
Warnick, RE	2
Gill, P	1
Litzow, M	1
Buckner, J	1
Arndt, C	1
Moynihan, T	1
Christianson, T	1
Ansell, S	1
Galanis, E	1
Sirohi, B	1
Cunningham, D	1
Powles, R	1
Murphy, F	1
Arkenau, T	1
Norman, A	1
Oates, J	1
Wotherspoon, A	1
Horwich, A	1
Jeremic, B	1
Grujicic, D	1
Antunovic, V	1
Djuric, L	1
Stojanovic, M	1
Shibamoto, Y	1
Liu, P	1
Leong, T	1
Quam, L	1
Billadeau, D	1
Kay, NE	1
Greipp, P	1
Kyle, RA	2
Oken, MM	1
Van Ness, B	1
Hochberg, F	1
Prados, M	1
Russell, C	1
Weissman, D	1
Evans, R	1
Cook, P	1
Burton, G	1
Eisenberg, PD	1
Valenzuela, R	1
Verkh, L	1
Brandes, AA	2
Scelzi, E	1
Zampieri, P	2
Rigon, A	2
Rotilio, A	1
Amista, P	1
Berti, F	1
Fiorentino, MV	1
Larson, DA	1
Lamborn, K	1
McDermott, MW	1
Sneed, PK	1
Wara, WM	1
Mack, EE	1
Krouwer, HG	1
Chandler, KL	1
Davis, RL	1
Rabbitt, JE	1
Malec, M	1
Levin, VA	1
Gutin, PH	1
Phillips, TL	1
Wilson, CB	1
Ermani, M	1
Carollo, C	1
Altavilla, G	1
Turazzi, S	1
Chierichetti, F	1
Florentino, MV	1
Yeh, KH	1
Uen, WC	1
Hung, RL	1
Liu, MY	1
Wang, CH	1
Taylor, BV	1
Buckner, JC	2
Cascino, TL	2
Schaefer, PL	1
Dinapoli, RP	1
Schomberg, P	1
Usnarska-Zubkiewicz, L	1
Gertz, MA	1
Lacy, MQ	1
Inwards, DJ	1
Chen, MG	1
Pineda, AA	1
Gastineau, DA	1
Greipp, PR	1
Lust, JA	1
Tefferi, A	1
Witzig, TE	1
Litzow, MR	1
Lassen, U	1
Kristjansen, PE	1
Wagner, A	1
Kosteljanetz, M	1
Poulsen, HS	1
Bogart, JA	1
Ungureanu, C	1
Ryu, S	1
Chung, CT	1
Zamkoff, KW	1
Hu, WW	2
Negrin, RS	2
Stockerl-Goldstein, K	2
Johnston, LJ	1
Shizuru, JA	1
Wong, RM	1
Chao, NJ	2
Long, GD	2
Feiner, RH	1
Blume, KG	2
Middleton, MR	1
Lorigan, P	1
Owen, J	1
Ashcroft, L	1
Lee, SM	1
Harper, P	1
Thatcher, N	1
Vlassenko, AG	1
Thiessen, B	1
Beattie, BJ	1
Malkin, MG	1
Blasberg, RG	1
Alvarnas, JC	1
Horning, SJ	1
Schriber, JR	1
Tierney, K	1
Wong, R	1
Berglund, A	1
Enblad, G	1
Carlson, K	1
Glimelius, B	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Use of TTFields for Newly Diagnosed GBM Patients in Germany in Routine Clinical Care - TIGER Study[NCT03258021]		710 participants (Actual)	Observational	2017-08-31	Active, not recruiting
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer[NCT03940196]	Phase 3	540 participants (Actual)	Interventional	2019-03-22	Active, not recruiting
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma[NCT03377491]	Phase 3	556 participants (Anticipated)	Interventional	2018-02-10	Active, not recruiting
HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma[NCT03128047]	Phase 1	6 participants (Actual)	Interventional	2017-04-06	Active, not recruiting
A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.[NCT00916409]	Phase 3	700 participants (Anticipated)	Interventional	2009-06-30	Completed
HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC)[NCT03606590]	Phase 2	25 participants (Actual)	Interventional	2019-02-15	Active, not recruiting
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).[NCT02831959]	Phase 3	270 participants (Anticipated)	Interventional	2016-07-31	Active, not recruiting
Use of TTFields in Germany in Routine Clinical Care Study PROgram - Daily Activity, Sleep and Neurocognitive Functioning in Newly Diagnosed Glioblastoma Patients Study[NCT04717739]		500 participants (Anticipated)	Observational	2021-12-30	Recruiting
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure[NCT02973789]	Phase 3	276 participants (Actual)	Interventional	2016-12-31	Active, not recruiting
A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment With Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects With Unresectable Gastroesophageal Junction (GEJ) Adenocarci[NCT04281576]		28 participants (Anticipated)	Interventional	2019-12-19	Recruiting
Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme[NCT00003417]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	1998-09-30	Completed
PHASE II TRIAL OF CHEMOTHERAPY PLUS RADIOTHERAPY FOR MANAGEMENT OF PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN'S LYMPHOMA (PCNSL)[NCT00002676]	Phase 2	36 participants (Actual)	Interventional	1995-07-31	Completed
A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas[NCT00003176]	Phase 2	82 participants	Interventional	1998-03-25	Completed
HIGH-DOSE MELPHALAN CHEMOTHERAPY AND TOTAL BODY RADIATION WITH PERIPHERAL BLOOD STEM-CELL RECONSTITUTION FOR PATIENTS WITH RELAPSING MULTIPLE MYELOMA[NCT00002630]	Phase 2	50 participants (Anticipated)	Interventional	1993-06-30	Completed
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases[NCT01703507]	Phase 1	17 participants (Actual)	Interventional	2012-11-09	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

(MTD) when combined with WBRT or SRS, defined as the last dose studied or the previous dose, based on clinical judgment of the degree of toxicity seen at the last dose (NCT01703507)
Timeframe: 30 days following the completion of radiation therapy

Number of Participants With Adverse Events and Serious Adverse Events

Overall Survival (OS) Rate

Progression Free Survival (PFS) Rate

Intervention	mg/kg (Number)
Arm A (Ipilimumab and Whole Brain Radiation Therapy)	3
Arm B (Ipilimumab and Stereotactic Radiosurgery)	10

Intervention	Participants (Count of Participants)
Arm A (Ipilimumab and Whole Brain Radiation Therapy)	1
Arm B (Ipilimumab and Stereotactic Radiosurgery)	4

Intervention	months (Median)
Arm A (Ipilimumab and Whole Brain Radiation Therapy)	8
Arm B (Ipilimumab and Stereotactic Radiosurgery)	10.5

PFS rate based on Response Evaluation Criteria in Solid Tumors (RECIST) and immune-related response criteria (irRC) criteria based on the brain MRI and systematic assessment by the treating physician (NCT01703507)
Timeframe: Up to 5 years

Rate of Developing New Brain Metastases in Each Arm

Response of Extracranial Disease

Intervention	Participants (Count of Participants)
Arm A (Ipilimumab and Whole Brain Radiation Therapy)	3
Arm B (Ipilimumab and Stereotactic Radiosurgery)	3

Intervention	months (Median)
Arm A (Ipilimumab and Whole Brain Radiation Therapy)	8.2
Arm B (Ipilimumab and Stereotactic Radiosurgery)	1.9

Extracranial disease is assessed through repeated computed tomography of the chest, abdomen, and pelvis. The purpose of this scan is to determine if there is any evidence of disease outside of the brain. (NCT01703507)
Timeframe: Up to 5 years

Article	Year
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. Journal of neuro-oncology, 2014, Volume: 118, Issue:3 Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B	2014
Current treatment of Cutaneous T-Cell Lymphoma. Dermatology online journal, 2001, Volume: 7, Issue:1 Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Apoptosis; Bexarotene; Biops	2001

Article	Year
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 2015, Dec-15, Volume: 314, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti	2015
Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. Journal of neuro-oncology, 2009, Volume: 95, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn	2009
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. International journal of radiation oncology, biology, physics, 2011, Oct-01, Volume: 81, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop	2011
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy, 2001, Volume: 3, Issue:3 Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodie	2001
Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Apr-15, Volume: 21, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols	2003
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jun-15, Volume: 21, Issue:12 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm	2003
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer, 2004, Apr-15, Volume: 100, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro	2004
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2004, Volume: 11, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr	2004
Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. Bone marrow transplantation, 2004, Volume: 34, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies;	2004
A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. Journal of neuro-oncology, 2005, Volume: 72, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms;	2005
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Nov-01, Volume: 11, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopla	2005
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood, 1996, Oct-01, Volume: 88, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Clone Cells; C	1996
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study. Journal of neuro-oncology, 1997, Volume: 32, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine	1997
Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. American journal of clinical oncology, 1997, Volume: 20, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo	1997
Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer, 1998, Jan-15, Volume: 82, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog	1998
Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm	1998
[Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma]. Polskie Archiwum Medycyny Wewnetrznej, 1998, Volume: 99, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease P	1998
Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. Journal of neuro-oncology, 1999, Volume: 43, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin;	1999
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. British journal of cancer, 2000, Volume: 82, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modalit	2000
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors. Leukemia, 2000, Volume: 14, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The	2000
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer, 2001, Jul-15, Volume: 92, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo	2001
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncology, 2001, Volume: 3, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies	2001
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dis	2002

Article	Year
Incomplete copolymer degradation of in situ chemotherapy. Journal of materials science. Materials in medicine, 2018, Feb-17, Volume: 29, Issue:3 Topics: Absorbable Implants; Adsorption; Aged; Brain Neoplasms; Carmustine; Disease Progression; Drug Delive	2018
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. Hematological oncology, 2019, Volume: 37, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progres	2019
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease. Leukemia & lymphoma, 2014, Volume: 55, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposi	2014
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial. Leukemia & lymphoma, 2015, Volume: 56, Issue:1 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmu	2015
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leukemia & lymphoma, 2015, Volume: 56, Issue:8 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cy	2015
Cerebral involvement as the first extracutaneous manifestation of mycosis fungoides. Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:8 Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brain; Carmusti	2015
[Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas]. No shinkei geka. Neurological surgery, 2015, Volume: 43, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb	2015
Role of deltaNp63(pos)CD44v(pos) cells in the development of N-nitroso-tris-chloroethylurea-induced peripheral-type mouse lung squamous cell carcinomas. Cancer science, 2016, Volume: 107, Issue:2 Topics: Animals; Carcinogens; Carcinoma, Squamous Cell; Carmustine; Disease Models, Animal; Disease Progress	2016
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Science translational medicine, 2016, 12-21, Volume: 8, Issue:370 Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carmu	2016
Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo. Cancer research, 2008, Jul-15, Volume: 68, Issue:14 Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Disease Progression; DNA Damage; E2F1 Transc	2008
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. Pediatric blood & cancer, 2008, Volume: 51, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transpla	2008
Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology, 2010, Volume: 255, Issue:2 Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chromatography, High Pressure Liquid; Con	2010
Concurrent treatment with BCNU and Gamma Knife radiosurgery in the rat malignant glioma model. Journal of neurological surgery. Part A, Central European neurosurgery, 2012, Volume: 73, Issue:3 Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Combined	2012
Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab. Annals of hematology, 2013, Volume: 92, Issue:7 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmu	2013
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood, 2002, Dec-15, Volume: 100, Issue:13 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo	2002
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo	2003
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin. Neurology, 2003, Oct-14, Volume: 61, Issue:7 Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas	2003
25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood. Chest, 2004, Volume: 126, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Disease Pr	2004
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M	2005
Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-15, Volume: 11, Issue:20 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Blotting, Western; Brain; Brain Neoplasms; Car	2005
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation Cancer, 2006, Jan-15, Volume: 106, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytid	2006
Imaging response in malignant glioma, RTOG 90-06. American journal of clinical oncology, 2007, Volume: 30, Issue:1 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Disease Progres	2007
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatric blood & cancer, 2008, Volume: 50, Issue:3 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine	2008
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-10, Volume: 26, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarab	2008
Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. Journal of neurosurgery, 2008, Volume: 108, Issue:2 Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain; Brain Neoplasms; Carmust	2008
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer, 2008, Apr-15, Volume: 112, Issue:8 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic;	2008
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin	2008
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. Journal of neuro-oncology, 1994, Volume: 21, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Ch	1994
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. International journal of radiation oncology, biology, physics, 1998, Jan-01, Volume: 40, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine	1998
Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol. Cancer, 1998, May-15, Volume: 82, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop	1998
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone marrow transplantation, 1999, Volume: 23, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow; Carm	1999
Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin disease. Radiology, 2000, Volume: 214, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas	2000
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2000, Volume: 6, Issue:1 Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; B	2000
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI. Journal of neuro-oncology, 2000, Volume: 46, Issue:3 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biologica	2000
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2000, Volume: 6, Issue:3A Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carm	2000
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. European journal of haematology, 2000, Volume: 65, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Co	2000
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. Italian journal of neurological sciences, 1999, Volume: 20, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy	1999
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood, 2000, Oct-15, Volume: 96, Issue:8 Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biom	2000
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. Bone marrow transplantation, 2000, Volume: 26, Issue:7 Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols	2000
Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. Journal of neuro-oncology, 2000, Volume: 49, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo	2000

carmustine and Disease Exacerbation